Christine Holtz
Adult Health · Spring Grove, PANPI 1093146540
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 376 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$620
- GSK$479
- Pfizer$361
- Lilly USA, LLC$330
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,266 |
| Novo Nordisk | 94 | $1,244 |
| AstraZeneca | 35 | $620 |
| GSK | 28 | $479 |
| Pfizer | 27 | $361 |
| Lilly USA, LLC | 16 | $330 |
| Exact Sciences | 9 | $230 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $189 |
| Bayer | 7 | $139 |
| Boehringer Ingelheim | 9 | $138 |
| Otsuka America Pharmaceutical, Inc. | 7 | $132 |
| Teva Pharmaceuticals USA, Inc. | 6 | $129 |
| Merck | 5 | $113 |
| E.r. Squibb & Sons, L.L.C. | 3 | $111 |
| Amgen | 5 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Phathom Pharmaceuticals, Inc. | 4 | $81 |
| Novartis | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Sanofi Pasteur Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Abbott | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Biogen | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Solventum Corporation | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Corium, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$6,222 in reported general payments places this provider in the 90th percentile of 899 adult health providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 94 | $86,897 |
| OzempicSemaglutide | 60 | $66,101 |
| JardianceEmpagliflozin | 62 | $52,892 |
| FarxigaDapagliflozin Propanediol | 52 | $49,532 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $29,085 |
| TrulicityDulaglutide | 11 | $28,627 |
| MounjaroTirzepatide | 29 | $28,579 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $19,394 |
| RybelsusSemaglutide | 11 | $9,892 |
| CystadaneBetaine | 11 | $9,278 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,822 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,345 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,055 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $2,781 |
| Memantine Hcl | 33 | $2,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $361 | $86,89794 claims |
| Novo NordiskOzempic, Rybelsus | $1,244 | $75,99371 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $138 | $64,76885 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $330 | $57,20640 claims |
| AstraZenecaFarxiga | $620 | $49,53252 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $479 | $34,43136 claims |
| AbbVieSynthroid | $1,266 | $2,38134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Spring Grove
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.